Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
188Re-PTI-6D2 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 188Re-PTI-6D2 | DRUG | monoclonal antibody |
Inclusion Criteria: * Histologically confirmed Stage IIIc (unresectable) or Stage IV metastatic melanoma; * measurable disease; * at least 18 years of age; * Karnofsky status at least 50%; * life expectancy \> 3 months; * at least 4 weeks since prior therapy; * adequate organ and marrow function de...
Top 20 of 48 competitors
188Re-PTI-6D2 is an investigational therapy being studied for the treatment of metastatic melanoma. It was evaluated in a Phase 1 safety study in patients with metastatic melanoma. The drug has not been approved for any indication and remains in clinical development.
188Re-PTI-6D2 is being developed by Filana Therapeutics, Inc., which trades under the ticker FLNA. The company sponsored the Phase 1 trial of the drug in metastatic melanoma.
188Re-PTI-6D2 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not received FDA approval.
188Re-PTI-6D2 has been evaluated in one completed Phase 1 trial, NCT00399113, titled "Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma." The trial enrolled 12 patients in Israel and was an uncontrolled, non-randomized study.
Yes, 188Re-PTI-6D2 is a biomarker-selected therapy. Its Phase 1 trial in metastatic melanoma, NCT00399113, required patients to meet a biomarker criterion for enrollment. The study enrolled 12 adults and was completed.